Amimestrocel (umbilical cord mesenchymal stromal cells) for acute kidney injury

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial gives Amimestrocel (human umbilical cord-derived mesenchymal stromal cells) to adults with acute kidney injury defined by the 2023 KDIGO criteria. Eligible participants are 18–75 years old and must meet KDIGO thresholds for serum creatinine rise or reduced urine output, with baseline creatinine estimated if prior values are unavailable. Participants receive the investigational cell therapy and are followed for safety and kidney outcomes such as changes in serum creatinine, urine output, and need for dialysis. The trial is run at tertiary hospitals in Beijing under the lead of the Chinese PLA General Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged between 18 and 75 years old; gender is not restricted.
2. According to the 2023 KDIGO diagnostic criteria for acute kidney injury (AKI), including those that occur during the course of the disease in various patients with chronic kidney disease (CKD), AKI can be diagnosed if any of the following conditions is met:

   ① The serum creatinine level increases by ≥ 26.5 μmol/L within 48 hours;

   ② The serum creatinine level increases by more than 1.5 times or higher than the baseline value within 7 days;

   ③ The urine output decreases (\< 0.5 mL/kg/h) and persists for more than 6 hours; The baseline value of serum creatinine: The lowest creatinine value obtained in the outpatient department or ward within 3 months, and the longest time limit is the creatinine value within 1 year. If there is no such value, the serum creatinine can be estimated using the MDRD equation under the assumption that the baseline eGFR is 75 ml/min/1.73m².
3. .Ability to give informed consent.

Exclusion Criteria:

1. Post-renal AKI.
2. Acute kidney injury caused by glomerular diseases such as rapidly progressive glomerulonephritis, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, anti-glomerular basement membrane antibody-mediated nephritis, vasculitis, cryoglobulinemia, thrombotic microangiopathy, etc.
3. Hemodynamic instability.
4. Severe cardiovascular diseases.
5. Severe pulmonary dysfunction.
6. A history of intracerebral hemorrhage or cerebral infarction within the past six months.
7. Subjects with abnormal laboratory indicators: AST or ALT \> 5 × upper limit of normal value (ULN); total bilirubin \> 3 × ULN; white blood cell count \< 2000/μL (2 × 10⁹/L), hemoglobin \< 6 g/dL (60 g/L), neutrophils \< 1000/μL (1 × 10⁹/L), platelets \< 50000/μL (50 × 10⁹/L).
8. Uncontrollable infection.
9. Patients with active hepatitis B or hepatitis C virus infection, active tuberculosis, severe immunodeficiency diseases, human immunodeficiency virus (HIV) infection, etc.
10. Received systemic immunosuppressants or glucocorticoid treatment for more than one week within 30 days before enrollment.
11. Have received hemodialysis or peritoneal dialysis treatment.
12. Have a history of hematopoietic stem cell transplantation or solid organ transplantation.
13. Patients with a history of malignant tumor within the past 5 years.
14. Life expectancy is less than 1 month.
15. Those with a known history of severe allergy to component blood or blood products, or those with a history of allergy to heterologous proteins.
16. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a fertility plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take contraceptive measures.
17. Patients who participated in other interventional clinical trials within 1 month before enrollment.

Where it's running

• Beijing hospital
  Beijing, Beijing Municipality, China Recruiting
• China-Japan Friendship Hospital
  Beijing, Beijing Municipality, China Recruiting
• Capital Medical University Affiliated Beijing Friendship Hospital
  Beijing, Beijing Municipality, China Recruiting
• Xuanwu Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Tsinghua Changgung Hospital, Medical Center, Tsinghua University
  Beijing, Beijing Municipality, China Not yet recruiting

Study contacts

• Study coordinator: xiangmei chen
• Email: liping.8@163.com
• Phone: 01066935462

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Restarting RAS inhibitors after AKI: a quick test in hospitalized adults

  This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT07734636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.